IL-27 promotes nitric oxide production induced by LPS through STAT1, NF-κB and MAPKs

Immunobiology

Volumn 218, Issue 4, 2013, Pages 628-634

  Shimizu, Motomu ^a,c   Ogura, Kiyoshi ^a   Mizoguchi, Izuru ^b   Chiba, Yukino ^b   Higuchi, Kaname ^b   Ohtsuka, Hiromi ^b   Mizuguchi, Junichiro ^b   Yoshimoto, Takayuki ^b  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

IL 27; INOS; LPS; Macrophages; NO

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 27; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; N(G) METHYLARGININE; NITRIC OXIDE; ONCOSTATIN M; REACTIVE NITROGEN SPECIES; STAT1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; THIOGLYCOLIC ACID; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CATALYSIS; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HOST RESISTANCE; LYMPHOCYTE DIFFERENTIATION; MICROGLIA; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TH17 CELL; TH2 CELL;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL NUCLEUS; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INTERLEUKINS; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MICE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OMEGA-N-METHYLARGININE; STAT1 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 4;

EID: 84875275310     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.07.028     Document Type: Article

References (47)

1. Awasthi A., Carrier Y., Peron J.P., Bettelli E., Kamanaka M., Flavell R.A., Kuchroo V.K., Oukka M., Weiner H.L. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 2007, 8:1380-1389.
2. Baker B.J., Park K.W., Qin H., Ma X., Benveniste E.N. IL-27 inhibits OSM-mediated TNF-alpha and iNOS gene expression in microglia. Glia 2010, 58:1082-1093.
3. Chakravortty D., Hensel M. Inducible nitric oxide synthase and control of intracellular bacterial pathogens. Microbes Infect. 2003, 5:621-627.
4. Chiyo M., Shimozato O., Iizasa T., Fujisawa T., Tagawa M. Antitumor effects produced by transduction of dendritic cells-derived heterodimeric cytokine genes in murine colon carcinoma cells. Anticancer Res. 2004, 24:3763-3767.
5. Chiyo M., Shimozato O., Yu L., Kawamura K., Iizasa T., Fujisawa T., Tagawa M. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int. J. Cancer 2005, 115:437-442.
6. Fitzgerald D.C., Zhang G.X., El-Behi M., Fonseca-Kelly Z., Li H., Yu S., Saris C.J., Gran B., Ciric B., Rostami A. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat. Immunol. 2007, 8:1372-1379.
7. Gearing D.P., Comeau M.R., Friend D.J., Gimpel S.D., Thut C.J., McGourty J., Brasher K.K., King J.A., Gillis S., Mosley B., et al. The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 1992, 255:1434-1437.
8. Gorina R., Font-Nieves M., Marquez-Kisinousky L., Santalucia T., Planas A.M. Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88-dependent NFkappaB signaling, MAPK, and Jak1/Stat1 pathways. Glia 2011, 59:242-255.
9. Guzzo C., Ayer A., Basta S., Banfield B.W., Gee K. IL-27 enhances LPS-induced proinflammatory cytokine production via upregulation of TLR4 expression and signaling in human monocytes. J. Immunol. 2012, 188:864-873.
10. Hibbert L., Pflanz S., De Waal Malefyt R., Kastelein R.A. IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J. Interferon Cytokine Res. 2003, 23:513-522.
11. Hibbs J.B. Synthesis of nitric oxide from l-arginine: a recently discovered pathway induced by cytokines with antitumour and antimicrobial activity. Res. Immunol. 1991, 142:565-569. (discussion 596-568).
12. Hisada M., Kamiya S., Fujita K., Belladonna M.L., Aoki T., Koyanagi Y., Mizuguchi J., Yoshimoto T. Potent antitumor activity of interleukin-27. Cancer Res. 2004, 64:1152-1156.
13. Ho M.Y., Leu S.J., Sun G.H., Tao M.H., Tang S.J., Sun K.H. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J. Immunol. 2009, 183:6217-6226.
14. Hu P., Hu H.D., Chen M., Peng M.L., Tang L., Tang K.F., Matsui M., Belladonna M.L., Yoshimoto T., Zhang D.Z., Xiang R., Ren H. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol. Immunol. 2009, 46:1654-1662.
15. Hunter C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 2005, 5:521-531.
16. Kamijo R., Harada H., Matsuyama T., Bosland M., Gerecitano J., Shapiro D., Le J., Koh S.I., Kimura T., Green S.J., et al. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 1994, 263:1612-1615.
17. Kamiya S., Owaki T., Morishima N., Fukai F., Mizuguchi J., Yoshimoto T. An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. J. Immunol. 2004, 173:3871-3877.
18. Korhonen R., Lahti A., Kankaanranta H., Moilanen E. Nitric oxide production and signaling in inflammation. Curr. Drug Targets Inflamm. Allergy 2005, 4:471-479.
19. Liu L., Wang S., Shan B., Shao L., Sato A., Kawamura K., Li Q., Ma G., Tagawa M. IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells. Scand. J. Immunol. 2008, 68:22-29.
20. MacMicking J., Xie Q.W., Nathan C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 1997, 15:323-350.
21. Mantovani A., Sica A., Locati M. Macrophage polarization comes of age. Immunity 2005, 23:344-346.
22. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 2009, 27:451-483.
23. Matsui M., Kishida T., Nakano H., Yoshimoto K., Shin-Ya M., Shimada T., Nakai S., Imanishi J., Yoshimoto T., Hisa Y., Mazda O. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res. 2009, 69:2523-2530.
24. Melillo G., Musso T., Sica A., Taylor L.S., Cox G.W., Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med. 1995, 182:1683-1693.
25. Meraz M.A., White J.M., Sheehan K.C., Bach E.A., Rodig S.J., Dighe A.S., Kaplan D.H., Riley J.K., Greenlund A.C., Campbell D., Carver-Moore K., DuBois R.N., Clark R., Aguet M., Schreiber R.D. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 1996, 84:431-442.
26. Nathan C., Xie Q.W. Nitric oxide synthases: roles, tolls, and controls. Cell 1994, 78:915-918.
27. Oniki S., Nagai H., Horikawa T., Furukawa J., Belladonna M.L., Yoshimoto T., Hara I., Nishigori C. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 2006, 66:6395-6404.
28. Pflanz S., Hibbert L., Mattson J., Rosales R., Vaisberg E., Bazan J.F., Phillips J.H., McClanahan T.K., de Waal Malefyt R., Kastelein R.A. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 2004, 172:2225-2231.
29. Pflanz S., Timans J.C., Cheung J., Rosales R., Kanzler H., Gilbert J., Hibbert L., Churakova T., Travis M., Vaisberg E., Blumenschein W.M., Mattson J.D., Wagner J.L., To W., Zurawski S., McClanahan T.K., Gorman D.M., Bazan J.F., de Waal Malefyt R., Rennick D., Kastelein R.A. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002, 16:779-790.
30. Pickens S.R., Chamberlain N.D., Volin M.V., Mandelin A.M., Agrawal H., Matsui M., Yoshimoto T., Shahrara S. Local expression of interleukin-27 ameliorates collagen-induced arthritis. Arthritis Rheum. 2011, 63:2289-2298.
31. Pot C., Apetoh L., Awasthi A., Kuchroo V.K. Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27. Semin. Immunol. 2011, 23:438-445.
32. Rivest S. Regulation of innate immune responses in the brain. Nat. Rev. Immunol. 2009, 9:429-439.
33. Salcedo R., Hixon J.A., Stauffer J.K., Jalah R., Brooks A.D., Khan T., Dai R.M., Scheetz L., Lincoln E., Back T.C., Powell D., Hurwitz A.A., Sayers T.J., Kastelein R., Pavlakis G.N., Felber B.K., Trinchieri G., Wigginton J.M. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J. Immunol. 2009, 182:4328-4338.
34. Salcedo R., Stauffer J.K., Lincoln E., Back T.C., Hixon J.A., Hahn C., Shafer-Weaver K., Malyguine A., Kastelein R., Wigginton J.M. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. J. Immunol. 2004, 173:7170-7182.
35. Shimizu M., Shimamura M., Owaki T., Asakawa M., Fujita K., Kudo M., Iwakura Y., Takeda Y., Luster A.D., Mizuguchi J., Yoshimoto T. Antiangiogenic and antitumor activities of IL-27. J. Immunol. 2006, 176:7317-7324.
36. Singh S., Gupta A.K. Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemother. Pharmacol. 2011, 67:1211-1224.
37. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 2009, 86:1065-1073.
38. Stumhofer J.S., Silver J.S., Laurence A., Porrett P.M., Harris T.H., Turka L.A., Ernst M., Saris C.J., O'Shea J.J., Hunter C.A. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat. Immunol. 2007, 8:1363-1371.
39. Takeda A., Hamano S., Yamanaka A., Hanada T., Ishibashi T., Mak T.W., Yoshimura A., Yoshida H. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 2003, 170:4886-4890.
40. Tendler D.S., Bao C., Wang T., Huang E.L., Ratovitski E.A., Pardoll D.A., Lowenstein C.J. Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis. Cancer Res. 2001, 61:3682-3688.
41. Villarino A., Hibbert L., Lieberman L., Wilson E., Mak T., Yoshida H., Kastelein R.A., Saris C., Hunter C.A. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 2003, 19:645-655.
42. Villarino A.V., Larkin J., Saris C.J., Caton A.J., Lucas S., Wong T., de Sauvage F.J., Hunter C.A. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J. Immunol. 2005, 174:7684-7691.
43. Wojno E.D., Hunter C.A. New directions in the basic and translational biology of interleukin-27. Trends Immunol. 2012, 33:91-97.
44. Xu M., Mizoguchi I., Morishima N., Chiba Y., Mizuguchi J., Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin. Dev. Immunol. 2010, 2010.
45. Yoshimoto T., Morishima N., Mizoguchi I., Shimizu M., Nagai H., Oniki S., Oka M., Nishigori C., Mizuguchi J. Antiproliferative activity of IL-27 on melanoma. J. Immunol. 2008, 180:6527-6535.
46. Yoshimoto T., Okada K., Morishima N., Kamiya S., Owaki T., Asakawa M., Iwakura Y., Fukai F., Mizuguchi J. Induction of IgG2a class switching in B cells by IL-27. J. Immunol. 2004, 173:2479-2485.
47. Yoshimoto T., Yoshimoto T., Yasuda K., Mizuguchi J., Nakanishi K. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J. Immunol. 2007, 179:4415-4423.